Capital International Investors Sells 6,597,100 Shares of AstraZeneca plc (AZN)

Capital International Investors cut its holdings in AstraZeneca plc (NYSE:AZN) by 39.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,967,710 shares of the company’s stock after selling 6,597,100 shares during the quarter. Capital International Investors owned approximately 0.39% of AstraZeneca worth $337,706,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in AZN. Russell Investments Group Ltd. grew its position in shares of AstraZeneca by 198.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,856,140 shares of the company’s stock worth $62,883,000 after buying an additional 1,235,239 shares during the period. Sector Gamma AS purchased a new stake in shares of AstraZeneca in the 3rd quarter worth about $25,094,000. Janus Henderson Group PLC grew its position in shares of AstraZeneca by 5,754.0% in the 3rd quarter. Janus Henderson Group PLC now owns 726,599 shares of the company’s stock worth $24,617,000 after buying an additional 714,187 shares during the period. Voya Investment Management LLC grew its position in shares of AstraZeneca by 38.2% in the 2nd quarter. Voya Investment Management LLC now owns 2,395,465 shares of the company’s stock worth $81,661,000 after buying an additional 662,481 shares during the period. Finally, Fisher Asset Management LLC grew its position in shares of AstraZeneca by 4.7% in the 3rd quarter. Fisher Asset Management LLC now owns 11,601,573 shares of the company’s stock worth $393,061,000 after buying an additional 519,717 shares during the period. 14.75% of the stock is currently owned by hedge funds and other institutional investors.

Shares of AstraZeneca plc (AZN) opened at $32.74 on Monday. AstraZeneca plc has a 1 year low of $26.51 and a 1 year high of $35.60. The company has a market cap of $82,896.44, a PE ratio of 7.81, a P/E/G ratio of 2.98 and a beta of 0.72. The company has a debt-to-equity ratio of 1.09, a quick ratio of 0.72 and a current ratio of 0.94.

AstraZeneca (NYSE:AZN) last announced its quarterly earnings data on Thursday, November 9th. The company reported $1.12 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.57 by $0.55. The company had revenue of $6.23 billion for the quarter, compared to the consensus estimate of $6 billion. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. AstraZeneca’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the prior year, the firm posted $1.32 EPS. equities analysts predict that AstraZeneca plc will post 1.87 earnings per share for the current fiscal year.

A number of research firms have recently weighed in on AZN. Liberum Capital downgraded shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Thursday, September 14th. BNP Paribas raised shares of AstraZeneca from a “neutral” rating to an “outperform” rating in a research report on Monday, September 25th. BMO Capital Markets reissued a “buy” rating and set a $38.00 price objective on shares of AstraZeneca in a research report on Tuesday, November 7th. Citigroup raised shares of AstraZeneca to a “buy” rating in a research report on Wednesday, October 18th. Finally, Sanford C. Bernstein raised shares of AstraZeneca from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $30.00 to $39.00 in a research report on Friday, September 22nd. Four research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $34.20.

TRADEMARK VIOLATION NOTICE: “Capital International Investors Sells 6,597,100 Shares of AstraZeneca plc (AZN)” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://stocknewstimes.com/2017/12/11/capital-international-investors-sells-6597100-shares-of-astrazeneca-plc-azn.html.

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply